Literature DB >> 7492081

Antimicrobial characterization and interrelationships of dirithromycin and epidirithromycin.

H A Kirst1, L C Creemer, J W Paschal, D A Preston, W E Alborn, F T Counter, J G Amos, R L Clemens, K A Sullivan, J M Greene.   

Abstract

Dirithromycin is the 9-N,11-O-oxazine adduct formed from 9(S)-erythromycylamine and 2-(2-methoxyethoxy)acetaldehyde in which the methoxyethoxymethyl substituent on the oxazine ring possesses the R configuration. Epidirithromycin is its isomer in which the methoxyethoxymethyl substituent has the opposite (S) configuration. Both compounds readily epimerize in solution, reaching an equilibrium ratio of 85:15 in favor of dirithromycin, given sufficient time. The rate of interconversion is dependent upon pH, temperature, and solvent. An enriched sample of epidirithromycin (95% purity) was synthesized by condensing erythromycylamine and 2-(2-methoxyethoxy)acetaldehyde in diethyl ether as the reaction solvent, and the product was fully characterized by nuclear magnetic resonance spectroscopy and high-pressure liquid chromatographic (HPLC) analysis. Both oxazine derivatives readily hydrolyze to erythromycylamine, so all three compounds exhibit the same antibiotic activity in vitro. In order to determine whether dirithromycin itself possesses significant antimicrobial activity without initial hydrolysis to erythromycylmine, inhibition of cell-free ribosomal protein synthesis was measured under conditions which were adapted to minimize hydrolysis, as measured by analytical HPLC in parallel experiments. Under these particular conditions, inhibition of ribosomal protein synthesis by dirithromycin was < 10% of the value measured for erythromycylamine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7492081      PMCID: PMC162758          DOI: 10.1128/AAC.39.7.1436

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Antibacterial activity of 9(S)-erythromycylamine-aldehyde condensation products.

Authors:  E H Massey; B S Kitchell; L D Martin; K Gerzon
Journal:  J Med Chem       Date:  1974-01       Impact factor: 7.446

2.  Epimerization of erythromycin derivatives.

Authors:  J Firl; A Prox; P Luger; R Maier; E Woitun; K Daneck
Journal:  J Antibiot (Tokyo)       Date:  1990-10       Impact factor: 2.649

3.  Synthesis and antimicrobial evaluation of dirithromycin (AS-E 136; LY237216), a new macrolide antibiotic derived from erythromycin.

Authors:  F T Counter; P W Ensminger; D A Preston; C Y Wu; J M Greene; A M Felty-Duckworth; J W Paschal; H A Kirst
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 4.  Intracellular distribution and activity of antibiotics.

Authors:  P M Tulkens
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

Review 5.  New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

6.  Hydrolysis of 2'-esters of erythromycin.

Authors:  J Taskinen; P Ottoila
Journal:  J Antimicrob Chemother       Date:  1988-06       Impact factor: 5.790

7.  Antibacterial activity of 2'-esters of erythromycin.

Authors:  P L Tardrew; J C Mao; D Kenney
Journal:  Appl Microbiol       Date:  1969-08
  7 in total
  1 in total

Review 1.  Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?

Authors:  M T Labro
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.